Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722140 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
ElectronicAdd to Basket



Amylin Pharmaceuticals, Inc.
Datamonitor, Sep 2008, Pages: 31


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

The Amylin Pharmaceuticals, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.

Amylin Pharmaceuticals (Amylin) is engaged in the discovery, development and commercialization of potential drug candidates for the treatment of diabetes and obesity. The company primarily focuses on investigating the potential utility of new peptide hormone candidates for the treatment of psychiatric indications. It has two marketed products in its portfolio, namely, Byetta and Symlin, for the treatment of diabetes. Amylin primarily operates in the US and Germany. The company is headquartered in San Diego, California and employed 1,900 people as of December 2007. The company recorded revenues of $781 million during the financial year (FY) ended December 2007, an increase of 52.9% over FY2006. The increase was primarily attributable to the continued strong growth in the product sales of Byetta and Symlin. The operating loss of the company was $243 million during FY2007, as compared to an operating loss of $237 million in FY2006. The net loss was $211 million in FY2007, as compared to a net loss of $219 million in FY2006.

Scope of the Report

- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement

Reasons to Purchase

- Support sales activities by understanding your customers’ businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors’ business structure, strategy and prospects
- Obtain the most up to date company information available


Customers who bought this item also bought

Amylin Pharmaceuticals, Inc. - SWOT Analysis

Premium Company Profile - Amylin Pharmaceuticals

Amylin Pharmaceuticals, Inc. - Financial and Strategic Analysis Review

Analysis of Amylin Pharmaceuticals

Amylin Pharmaceuticals - SWOT Framework Analysis

Amylin Pharmaceuticals, Inc.

Auxilium Pharmaceuticals, Inc.

Progenics Pharmaceuticals, Inc.

Achillion Pharmaceuticals, Inc.

Idenix Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc. - SWOT Analysis

Noven Pharmaceuticals, Inc. - SWOT Analysis



Top of page


   All rights reserved. © Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds